Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference103 articles.
1. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies;Gerber;Cancer Res,2005
2. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies;Zondor;Ann Pharmacother,2004
3. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis;Hicklin;J Clin Oncol,2005
4. Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers;Rosen;Cancer Control,2002
5. Angiogenesis and lung cancer: Prognostic and therapeutic implications;Herbst;J Clin Oncol,2005
Cited by 432 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy;International Journal of Molecular Sciences;2024-01-23
2. TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review;Frontiers in Oncology;2023-12-13
3. Immunogenic chemotherapy: great potential for improving response rates;Frontiers in Oncology;2023-12-06
4. Anti-angiogenic Drug Resistance: Roles and Targeting of Non-coding RNAs (microRNAs and long non-coding RNAs);Current Molecular Pharmacology;2023-12
5. Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review;Medical Oncology;2023-11-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3